Survey of treatment and care practices in small-cell lung cancer among German radiation oncologists.
Atezolizumab
Chemotherapy
Immunotherapy
Prophylactic cranial irradiation
Radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
20
02
2022
accepted:
09
10
2022
medline:
22
6
2023
pubmed:
24
11
2022
entrez:
23
11
2022
Statut:
ppublish
Résumé
The management of small-cell lung cancer shows differences, particularly with regard to the use of radio- (RT), chemo-, and immunotherapy. We performed a survey among German radiation oncologists to assess the management of small-cell lung cancer (SCLC). A 34-question online survey was created and sent out by e‑mail to radiation oncologists throughout Germany. The survey period extended from August 2020 to January 2021. The questions addressed indications for RT, planning techniques, dosing/fractionation, target volume definition for consolidative thoracic irradiation, and the use of prophylactic cranial irradiation (PCI). At the same time, we surveyed the use of atezolizumab. The survey addressed the treatment practice for limited-stage SCLC (LS-SCLC) and extensive-stage SCLC (ES-SCLC). We received 74 responses. In LS-SCLC, treatment is planned predominantly based on diagnostic information from computed tomography (CT) of the thorax/abdomen/pelvis (88%), PET-CT (86%), and pulmonary function testing (88%). In LS-SCLC, 99% of respondents perform radiation concurrently with chemotherapy, preferably starting with cycle one or two (71%) of chemotherapy. The most common dose and fractionation schedule was 60-66 Gy in 30-33 fractions (once daily: 62% of all respondents). In ES-SCLC, 30 Gy in 10 fractions (once daily: 33% of all respondents) was the most commonly used regimen in consolidative thoracic irradiation. Only 25% use chemosensitization with RT. The inclusion criteria for PCI were similar for limited and extensive disease, with Karnofsky index (78% and 75%) being the most important decision factor. Respondents use a schedule of 30 Gy in 15 fractions most frequently in both stages (68% limited stage [LS], 60% extensive stage [ES]). Immunotherapy was used regularly or occasionally in LS-SCLC by 45% of respondents, with reduced lung function (37%), cardiac comorbidities (30%), and hepatic insufficiency (30%) being the most commonly mentioned exclusion criteria for this form of therapy. In ES-SCLC, atezolizumab use was reported in 78% of all questionnaires. Half of the respondents (49%) administer it simultaneously with cranial irradiation. Our survey showed variability in the management of SCLC. Results from future studies might help to clarify open questions regarding the optimal treatment paradigms. In addition, new treatment modalities, such as immunotherapy, might change practices in the near future.
Sections du résumé
BACKGROUND
The management of small-cell lung cancer shows differences, particularly with regard to the use of radio- (RT), chemo-, and immunotherapy. We performed a survey among German radiation oncologists to assess the management of small-cell lung cancer (SCLC).
METHODS
A 34-question online survey was created and sent out by e‑mail to radiation oncologists throughout Germany. The survey period extended from August 2020 to January 2021. The questions addressed indications for RT, planning techniques, dosing/fractionation, target volume definition for consolidative thoracic irradiation, and the use of prophylactic cranial irradiation (PCI). At the same time, we surveyed the use of atezolizumab. The survey addressed the treatment practice for limited-stage SCLC (LS-SCLC) and extensive-stage SCLC (ES-SCLC).
RESULTS
We received 74 responses. In LS-SCLC, treatment is planned predominantly based on diagnostic information from computed tomography (CT) of the thorax/abdomen/pelvis (88%), PET-CT (86%), and pulmonary function testing (88%). In LS-SCLC, 99% of respondents perform radiation concurrently with chemotherapy, preferably starting with cycle one or two (71%) of chemotherapy. The most common dose and fractionation schedule was 60-66 Gy in 30-33 fractions (once daily: 62% of all respondents). In ES-SCLC, 30 Gy in 10 fractions (once daily: 33% of all respondents) was the most commonly used regimen in consolidative thoracic irradiation. Only 25% use chemosensitization with RT. The inclusion criteria for PCI were similar for limited and extensive disease, with Karnofsky index (78% and 75%) being the most important decision factor. Respondents use a schedule of 30 Gy in 15 fractions most frequently in both stages (68% limited stage [LS], 60% extensive stage [ES]). Immunotherapy was used regularly or occasionally in LS-SCLC by 45% of respondents, with reduced lung function (37%), cardiac comorbidities (30%), and hepatic insufficiency (30%) being the most commonly mentioned exclusion criteria for this form of therapy. In ES-SCLC, atezolizumab use was reported in 78% of all questionnaires. Half of the respondents (49%) administer it simultaneously with cranial irradiation.
CONCLUSION
Our survey showed variability in the management of SCLC. Results from future studies might help to clarify open questions regarding the optimal treatment paradigms. In addition, new treatment modalities, such as immunotherapy, might change practices in the near future.
Identifiants
pubmed: 36418442
doi: 10.1007/s00066-022-02019-9
pii: 10.1007/s00066-022-02019-9
pmc: PMC10281900
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
631-644Informations de copyright
© 2022. The Author(s).
Références
Strahlenther Onkol. 2020 Feb;196(2):172-181
pubmed: 31784801
BMC Cancer. 2019 Jan 21;19(1):95
pubmed: 30665432
Ann Oncol. 2016 Oct;27(10):1818-28
pubmed: 27436850
Strahlenther Onkol. 2018 Dec;194(12):1152-1162
pubmed: 30218136
Strahlenther Onkol. 2018 Oct;194(10):876-885
pubmed: 29774395
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Curr Oncol. 2016 Jun;23(3):184-95
pubmed: 27330347
JAMA Netw Open. 2020 Oct 1;3(10):e2015748
pubmed: 33074323
Eur J Cardiothorac Surg. 1991;5(6):306-9; discussion 310
pubmed: 1651741
Ann Oncol. 2020 Feb;31(2):310-317
pubmed: 31959349
N Engl J Med. 2007 Aug 16;357(7):664-72
pubmed: 17699816
Lancet Oncol. 2017 Aug;18(8):1116-1125
pubmed: 28642008
Lancet Oncol. 2021 Mar;22(3):321-331
pubmed: 33662285
J Clin Oncol. 1993 Feb;11(2):336-44
pubmed: 8381164
Strahlenther Onkol. 2021 Sep;197(9):1-23
pubmed: 34259912
Lancet Oncol. 2017 May;18(5):663-671
pubmed: 28343976
J Thorac Oncol. 2019 Feb;14(2):294-297
pubmed: 30292850
J Thorac Oncol. 2018 Jun;13(6):840-848
pubmed: 29526825
Lancet Oncol. 2021 Jan;22(1):51-65
pubmed: 33285097
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641